Genzyme Corporation

Alexandra Joseph

Susan Richards

Yibin Xiang

Zhong Zhao

Christopher Yee

Andrew T Papoulis

Paul Mason

Jill Gregory

Mohamud Mohamud

Sanjay Danthi

Yiding Hu

Yinyin Huang

Melanie Ruzek

Kara Carter

Richard Garman

Johnson Tran

Andrew Papoulis

The present application provides methods of treating a disease, such as Pompe disease, in a subject, comprising detecting an erythropoiesis biomarker in a sample of the subject after administration of methotrexate and a therapeutic agent to the subject, and administering further treatment with or without concurrently administering additional immune tolerance induction or immunosuppression therapy based on the level of the erythropoiesis biomarker. Further provided by the present application are methods and kits for assessing the level of immune tolerance to a therapeutic agent in a subject based on detection of an erythropoiesis biomarker after administration of methotrexate and the therapeutic agent to the subject.

Biomarkers of methotrexate-induced immune tolerance

The invention provides methods for reducing undesired immune responses, such as anti-drug antibody (ADA) responses and other T- and/or B-cell-mediated immune responses, in patients by using treatment with methotrexate.

Induction of immune tolerance by using methotrexate

The invention features compounds of Formula (I), Formula (I)-A and Formula (I)-B as disclosed herein, as well as methods of synthesis, therapy, diagnostics, and assays. 

NAMPT inhibitors and methods

Growing community of inventors

Lexington, MA, United States of America

Alexandra Joseph